About this Research Topic
Around 400 million Hepatitis B virus carriers are estimated in the world. Hepatitis B virus infection may lead to Chronic Hepatitis B (CHB) disease. Acute Exacerbation (AE) of CHB is characterized by impairment of liver function following the rise of the virus DNA and has been reported to have a cumulative incidence of 10%-30% every year. AE can also develop in CHB patients who received cytotoxic chemotherapy or immunomodulatory agents.
CHB with AE can be mild, but some patients may develop a severe course such as hepatic decompensation and even mortality. The underlying pathogenesis is not quite clear but is usually attributed to the activation of T lymphocyte-mediated immune response targeting HBV.
Whether the antiviral treatment for CHB with severe AE improves clinical outcome remains controversial but some nucleo(s)tide analogs (NUCs) have been used in the treatment of this disease. Nevertheless, there is a lack of randomized controlled studies that compare the effects of different NUCs in the CHB with severe AE treatment.
With the above in mind, the scope of this Research Topic is to expand our knowledge regarding the natural history, pathogenic mechanisms, prognostic factors, and therapeutic options of CHB with AE.
We welcome Review Articles, Original Research, Brief research Reports, Clinical Trials, which investigate the following research questions:
• Pathogenetic mechanisms of CHB with AE
• Natural history of CHB with AE with or without NUCs treatment
• Prognostic factors associated with CHB with AE.
• Therapeutic benefits of different NUCs alone or in combination for CHB with AE
• Clinical outcome of NUCs withdrawal AE
• Therapeutic options for the prevention of AE in CHB undergoing cytotoxic chemotherapy or immuno-modulatory agents
Keywords: Hepatitis B, Acute exacerbation, Nucleos(t)ide analogue, chemotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.